Merkel cell polyomavirus (MCPyV) status
About eight in ten Merkel cell carcinomas are driven by a common skin virus that has stitched itself into the tumour's DNA; the virus-negative rest are driven by sunlight and carry a huge mutation load. Both respond to immunotherapy, and in virus-positive patients a blood antibody test against the viral protein can track the cancer after treatment.
Overview
What is measured: whether a Merkel cell carcinoma carries integrated Merkel cell polyomavirus, and the patient's antibody response to its oncoproteins. How: immunohistochemistry for the viral large T antigen (CM2B4 antibody) or PCR for viral DNA on the tumour; serum antibodies to the small and large T oncoproteins (the AMERK test) in about half of patients at diagnosis, whose titre falls after successful treatment and rises months before a recurrence is visible (antibodies to the capsid protein are common in healthy people and useless). Virus-negative tumours carry an ultraviolet mutational signature, very high tumour mutational burden and TP53 and RB1 mutations; virus-positive tumours have few mutations yet respond just as well to PD-1 and PD-L1 blockade (avelumab in JAVELIN Merkel 200, pembrolizumab in KEYNOTE-017, retifanlimab). What a result changes: prognosis (virus-positive slightly better), the surveillance strategy (serial titres in seropositive patients in place of some imaging), stratification in trials, and eligibility for T-cell therapies directed at viral antigens. Where it matters: Merkel cell carcinoma.
Similar pages
not linked directly; found by shared links- TrialPlacebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Car
Shares Merkel cell carcinoma, Pembrolizumab.
- IdeaA standard evolvability score for every tumour
Shares Mutational signature, Tumour mutational burden (TMB).
- TrialQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Shares Avelumab, Merkel cell carcinoma, Pembrolizumab.
- TrialJAVELIN Merkel 200
Shares Avelumab, Merkel cell carcinoma.
- TrialA Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)
Shares Merkel cell carcinoma, Pembrolizumab.
- TrialKEYNOTE-017 (Cancer Immunotherapy Trials Network 09)
Shares Merkel cell carcinoma, Pembrolizumab.
- TrialStudy of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Shares Avelumab, Pembrolizumab.
- PersonAurélien Marabelle